{"id":60385,"date":"2024-11-23T01:02:28","date_gmt":"2024-11-23T00:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/"},"modified":"2024-11-23T01:02:28","modified_gmt":"2024-11-23T00:02:28","slug":"quanterix-announces-receipt-of-expected-notice-from-nasdaq","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/","title":{"rendered":"Quanterix Announces Receipt of Expected Notice from Nasdaq"},"content":{"rendered":"
\n

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation <\/b>(NASDAQ: QTRX) today announced that it received a notice (the \u201cNotice\u201d) on November 21, 2024 from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the \u201cForm 10-Q”), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the \u201cRule\u201d), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the \u201cSEC\u201d).<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe Notice has no immediate effect on the listing or trading of the Company\u2019s common stock on Nasdaq. Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice, or until January 20, 2025, to submit a plan to regain compliance with the Rule.<\/p>\n

\nOn November 12, 2024, the Company previously announced that it would be delayed in filing the Form 10-Q due to the need to restate the Company\u2019s audited consolidated financial statements as of December 31, 2023 and 2022 and for each of the three years in the period ended December 31, 2023, and its unaudited consolidated financial statements for the quarterly and year-to-date (as applicable) periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023, September 30, 2023, March 31, 2024 and June 30, 2024. The Notice from Nasdaq is standard practice in the event of a delayed periodic financial report filing and was anticipated.<\/p>\n

\nThe Company is continuing to work expeditiously to complete the filing of the Form 10-Q and remains on track to complete the restatement and all required filings by the end of 2024.<\/p>\n

\nThis announcement is made in compliance with Nasdaq Listing Rule 5250(b)(2).<\/p>\n

\nAbout Quanterix<\/b><\/p>\n

\nFrom discovery to diagnostics, Quanterix\u2019s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company\u2019s Simoa\u00ae <\/sup>technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https:\/\/www.quanterix.com<\/a> or follow us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release are based on Quanterix\u2019s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix\u2019s actual results to differ from those expressed or implied in the forward-looking statements in this press release include, but are not limited to, that the Company may have underestimated the scope and impact of the restatement of certain of its financial statement and the risk that the Company\u2019s restated financial statements may take longer to complete than expected, as well as those described in our periodic reports filed with the U.S. Securities and Exchange Commission, including the \u201cRisk Factors\u201d sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:
\n
media@quanterix.com<\/a><\/p>\n

\nInvestor Relations:
\n
Amy Achorn
\n
(978) 488-1854
\n
ir@quanterix.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the \u201cNotice\u201d) on November 21, 2024 from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the \u201cForm 10-Q”), it is no longer … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60385","6":"format-standard","7":"category-industry"},"yoast_head":"\nQuanterix Announces Receipt of Expected Notice from Nasdaq - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quanterix Announces Receipt of Expected Notice from Nasdaq - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the \u201cNotice\u201d) on November 21, 2024 from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the \u201cForm 10-Q”), it is no longer ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-23T00:02:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241122959546\/en\/2314297\/22\/QTRX_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Quanterix Announces Receipt of Expected Notice from Nasdaq\",\"datePublished\":\"2024-11-23T00:02:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/\"},\"wordCount\":608,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241122959546\\\/en\\\/2314297\\\/22\\\/QTRX_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/\",\"name\":\"Quanterix Announces Receipt of Expected Notice from Nasdaq - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241122959546\\\/en\\\/2314297\\\/22\\\/QTRX_Logo.jpg\",\"datePublished\":\"2024-11-23T00:02:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241122959546\\\/en\\\/2314297\\\/22\\\/QTRX_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241122959546\\\/en\\\/2314297\\\/22\\\/QTRX_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quanterix Announces Receipt of Expected Notice from Nasdaq\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quanterix Announces Receipt of Expected Notice from Nasdaq - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/","og_locale":"en_US","og_type":"article","og_title":"Quanterix Announces Receipt of Expected Notice from Nasdaq - Pharma Trend","og_description":"BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the \u201cNotice\u201d) on November 21, 2024 from The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the \u201cForm 10-Q”), it is no longer ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/","og_site_name":"Pharma Trend","article_published_time":"2024-11-23T00:02:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241122959546\/en\/2314297\/22\/QTRX_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Quanterix Announces Receipt of Expected Notice from Nasdaq","datePublished":"2024-11-23T00:02:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/"},"wordCount":608,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241122959546\/en\/2314297\/22\/QTRX_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/","url":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/","name":"Quanterix Announces Receipt of Expected Notice from Nasdaq - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241122959546\/en\/2314297\/22\/QTRX_Logo.jpg","datePublished":"2024-11-23T00:02:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241122959546\/en\/2314297\/22\/QTRX_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241122959546\/en\/2314297\/22\/QTRX_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/quanterix-announces-receipt-of-expected-notice-from-nasdaq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Quanterix Announces Receipt of Expected Notice from Nasdaq"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60385"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60385\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}